Search
Oftasceine
go.drugbank.com/drugs/DB11184ApprovedIt is used in ophthalmic solutions as a staining agent when fitting soft and hard lenses. It is a fluorescent dye or luminescent agent.
Aspartyl-alanyl-diketopiperazine
go.drugbank.com/drugs/DB14940InvestigationalAspartyl-alanyl-diketopiperazine is under investigation in clinical trial NCT03349645 (An Open Label Extension Study to Assess the Safety of Long-Term Treatment With Ampion for Severe OA of the Knee).
EU204
go.drugbank.com/drugs/DB17438InvestigationalEU204 (EBViNT) is an Epstein-Barr virus (EBV)-positive T-cell therapy currently undergoing phase 1 and 2a clinical trials in Korea for patients with EBV-positive lymphoma and solid cancer.
COVID-19 Spike-GM-CSF Protein Lactated Ringer's Injection
go.drugbank.com/drugs/DB16520ExperimentalCOVID-19 Spike-GM-CSF Protein Lactated Ringer's Injection is an intradermal injection currently being investigated in the clinical trial NCT03348670 (Discovery Stage (Proof-of-concept) COVID-19 Antigen
Caroxazone
go.drugbank.com/drugs/DB09254ApprovedWithdrawnCaroxazone is an antidepressant that has been withdrawn from the market. It is a reversible monoamine oxidase inhibitor (MAOI) of both A and B monoamine oxidase subtypes.
Ginseng
go.drugbank.com/drugs/DB01404ApprovedInvestigationalNutraceuticalGinseng is promoted as an adaptogen (a product that increases the body's resistance to stress), one which can to a certain extent be supported with reference to its anticarcinogenic and antioxidant properties
Mixtures: GINSENG-E CAPSULECategories: Complex MixturesFavId
go.drugbank.com/drugs/DB05249InvestigationalFavId, is an active immunotherapy that is based upon unique genetic information extracted from a patient's tumor.
CG7870
go.drugbank.com/drugs/DB04981InvestigationalCG7870 is an oncolytic virus therapy for prostate cancer.
AN0128
go.drugbank.com/drugs/DB05054InvestigationalAN0128 is a novel compound that contains a boron atom within a borinic acid complex. … Of particular importance is P. acnes and its causal role in acne vulgaris. The rise in antibiotic resistance of P. acnes to standard antibiotics necessitates the development of new treatment agents.